GO
Loading...

Enter multiple symbols separated by commas

Search results for "TEVA"

REFINE RESULTS

SEARCH RESULTS

About 76 results. Sort By: Date | Relevance
CNBC update: Mysterious oil globs in LA  

Coast guard scientists are investigating mysterious balls of tar washing ashore in Los Angeles County, and Teva will pay a $1.2 billion settlement, reports CNBC's Sharon Epperson.
Source: CNBC.com
UPDATE 2-U.S. settles 'pay-for-delay' fight with drugmaker Teva over Provigil

WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday. As part of the settlement, Teva, which bought Cephalon in 2012, agreed to pay $1.2 billion to refund...
Source: Reuters | By: Diane Bartz
Teva pays $1.2 billion to settle pay-for-delay allegations

WASHINGTON- Federal regulators say Teva Pharmaceuticals Industries will pay $1.2 billion to settle charges that one of its subsidiaries illegally blocked the launch of generic versions of the blockbuster sleeping pill Provigil. But Federal Trade Commission officials say the agreements keep cheaper forms of medicines off the market, driving up costs for...
Source: The Associated Press
UPDATE 1-U.S. settles 'pay for delay' fight with drugmaker Cephalon

WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit tied to wakefulness drug Provigil, the Federal Trade Commission said on Thursday. As part of the settlement with regulators, Teva, which bought Cephalon in 2012, agreed to pay $1.2...
Source: Reuters
U.S. settles 'pay for delay' fight with drugmaker Cephalon

WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil, the Federal Trade Commission said on Thursday. Cephalon had been accused by the FTC of illegally protecting its monopoly on Provigil by...
Source: Reuters
Early movers: BRCM, COST, EXPR, ANF & more

These are the stocks posting the largest moves before the bell.
Source: CNBC.com | By: Peter Schacknow
6 trades on big day for chip makers

Intel, Qualcomm and Broadcom all saw big gains on Wednesday, and "Fast Money" traders discussed which names have more room to run.
Source: CNBC.com | By: Jacob Pramuk
Your first trade for Thursday

The "Fast Money" traders give their final trades of the day.
Source: CNBC.com | By: Leanne Miller
After-hours buzz: Palo Alto, Teva, Analog & more

Check out the companies making headlines after the bell Wednesday: Palo Alto, Teva, Analog Devices & more.
Source: CNBC.com | By: Karma Allen
Teva discloses 1.35 pct stake in target Mylan

May 27- Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV, saying the purchase underscored its commitment to buy Mylan as soon as possible. Teva proposed to buy Mylan for $82 per share, or about $43 billion, in cash and stock last month. Mylan rejected the offer saying it "grossly undervalued" the company, setting up a three-way battle...
Source: Reuters